Patent · US Active

Methods of reducing CRP and/or increasing serum albumin in patients in need using IL-6 antibodies of defined epitopic specificity

US8535671B2 · kind B2 · utility

26Cited by
75References
28Claims
0Family size

Assignee

Inventor

Key dates

Filing dateSep 22, 2011
Grant dateSep 17, 2013
Priority date
Expiry dateSep 22, 2031

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.